RGEN - レプリジェン (Repligen Corporation) レプリジェン

 RGENのチャート


 RGENの企業情報

symbol RGEN
会社名 Repligen Corp. (レプリジェン)
分野(sector) Health Care   ヘルスケア
産業(industry) Biotechnology: Biological Products (No Diagnostic Substances)  
業種 医薬品   医療関連(Health Care)
概要 事業概要 レプリゲン(Repligen Corporation)はバイオプロセス会社である。同社は生物医薬品製造プロセスの相互接続段階を改善するために使用される製品の開発、製造、および商品化に注力する。同社のポートフォリオには、タンパク質製品、クロマトグラフィー製品、ろ過製品が含まれる。同社は市場または開発中のモノクローナル抗体(mAb)ベースの薬物の精製に使用されるプロテインAクロマトグラフィー樹脂の成分であるプロテインAリガンドを提供する。クロマトグラフィーのポートフォリオには生物学的薬剤の下流精製および品質管理に使用される製品が含まれる。OPUSプレパッククロマトグラフィーカラム(PPC)は臨床段階の生物製剤の精製に使用される。ろ過製品には、XCell交互タンジェンシャル・フロー(ATF)システムおよびSiusタンジェンシャル・フロー・フィルトレーション(TFF)カセットが含まれる。Sius TFFカセットは臨床および商業段階の生物製剤を濃縮するために使用される。   レプリジェンは米国のバイオテクノロジ―企業。世界の生命科学企業やバイオ医薬品メ―カ―向けに、生物学的処理に使用される製品の開発、製造、販売を行う。中央神経系疾患の治療薬開発を中心に事業を展開する。また、モノクロ―ナル抗体治療薬の分離と精製に用いられる、親和性リガンド「プロテインA」の製造に従事。本社はマサチュ―セッツ州。   Repligen Corporation is a global life sciences company that develops and commercializes highly innovative bioprocessing technologies and systems that increase efficiencies in the process of manufacturing biological drugs. Its primary customers are biopharmaceutical drug developers and contract development and manufacturing organizations (CDMOs) worldwide. Its corporate headquarters are located in Waltham, Massachusetts, with additional administrative and manufacturing operations worldwide. The majority of its manufacturing sites are located within the U.S. (California, Massachusetts, New Jersey and New York), and outside of the U.S. it has sites in Estonia, Germany, Ireland, the Netherlands and Sweden.
本社所在地 41 Seyon Street Bldg. 1 Suite 100 Waltham MA 02453 USA
代表者氏名 Karen A. Dawes カレンA.ダウズ
代表者役職名 Independent Chairperson of the Board
電話番号 +1 781-449-9560
設立年月日 29707
市場名 NASDAQ National Market System
ipoyear 1986年
従業員数 476人
url www.repligen.com
nasdaq_url https://www.nasdaq.com/symbol/rgen
adr_tso
EBITDA EBITDA(百万ドル) 28.26800
終値(lastsale) 54.7
時価総額(marketcap) 2396177369.4
時価総額 時価総額(百万ドル) 2415.89
売上高 売上高(百万ドル) 170.75300
企業価値(EV) 企業価値(EV)(百万ドル) 2341.608
当期純利益 当期純利益(百万ドル) 13.44700
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Repligen Corporation revenues increased 47% to $92.6M. Net income decreased 46% to $6.2M. Revenues reflect North America segment increase from $11.6M to $42.7M. Net income was offset by Other selling increase of 30% to $23.2M (expense) Research and development - Balancing val increase from $3.4M to $8.7M (expense).

 RGENのテクニカル分析


 RGENのニュース

   2021-2027 Tangential Flow Filtration Market Trending Technologies, Remarkable Developments and Key Players like GE, Merck, Sartorius, Repligen, Parker Hannifin, Sterlitech, Bionet  2021/09/27 11:07:47 OpenPR
Overview of Global Tangential Flow Filtration Market: The universal Tangential Flow Filtration Market report gives us an in-depth overview of the research trends for the financial year 2021. The base year for calculation in the report is taken as 2020 while
   The Daily Biotech Pulse: Pfizer-BioNTech US Vaccine Contract, Summit Slumps On Adverse Regulatory Feedback, Cerevel CFO Departs  2021/09/22 11:45:28 Benzinga
Here''s a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 20) Acceleron Pharma Inc. (NASDAQ: XLRN ) Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH ) C4 Therapeutics, Inc. (NASDAQ: CCCC ) Cerevel Therapeutics Holdings, Inc. (NASDAQ: CERE ) Corvus Pharmaceuticals, Inc. NASDAQ: CRVS) Fulcrum Therapeutics, Inc. (NASDAQ: FULC ) IVERIC bio, Inc. (NASDAQ: ISEE ) Leap Therapeutics, Inc. (NASDAQ: LPTX ) Opiant Pharmaceuticals, Inc. (NASDAQ: OPNT ) Repligen Corporation (NASDAQ: RGEN ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows Sept. 20) Ambrx Biopharma Inc. (NYSE: AMAM ) Absci Corporation (NASDAQ: ABSI ) Acutus Medical, Inc. (NASDAQ: AFIB ) Aytu Biopharma, Inc. (NASDAQ: AYTU ) AzurRx BioPharma, Inc. (NASDAQ: AZRX ) Biomea Fusion, Inc. (NASDAQ: BMEA ) Centessa Pharmaceuticals Limited (NASDAQ: CNTA ) Codex DNA, Inc. (NASDAQ: DNAY ) Emergent BioSolutions Inc. (NYSE: EBS ) Galapagos NV (NASDAQ: GLPG ) Harpoon Therapeutics, Inc.
   The Daily Biotech Pulse: Leap, Phio, Silverback Among Early Movers On Oncology Conference Presentations, Aerie Slumps On Mixed Data, Axsome Commences Phase 3 Sleep Disorder Study  2021/09/16 11:48:49 Benzinga
Here''s a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 15) Alcon Inc. (NYSE: ALC ) Bicycle Therapeutics plc (NASDAQ: BCYC ) Bio-Techne Corporation (NASDAQ: TECH ) Cytek Biosciences, Inc. (NASDAQ: CTKB ) Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA ) IVERIC bio, Inc. (NASDAQ: ISEE ) Kezar Life Sciences, Inc. (NASDAQ: KZR ) Opiant Pharmaceuticals, Inc. (NASDAQ: OPNT ) Repligen Corporation (NASDAQ: RGEN ) Vera Therapeutics, Inc. (NASDAQ: VERA ) Zentalis Pharmaceuticals, Inc. (NASDAQ: ZNTL ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows Sept. 15) 4D pharma plc (NASDAQ: LBPS ) (announced biomarker analyses from two studies of MRx0518 in solid tumor settings) Achilles Therapeutics plc (NASDAQ: ACHL ) Acutus Medical, Inc. (NASDAQ: AFIB ) Aditxt, Inc. (NASDAQ: ADTX ) Applied Molecular Transport Inc. (NASDAQ: AMTI ) Ardelyx, Inc. (NASDAQ: ARDX ) AzurRx BioPharma, Inc. (NASDAQ: AZRX ) CVRx, Inc. (NASDAQ: CVRX ) Dermata Therapeutics, Inc.
   Repligen acquires Avitide in cash and stock deal of $150M  2021/09/16 11:47:27 Seeking Alpha
   Repligen Announces Agreement to Acquire Avitide Inc.  2021/09/16 11:40:00 Intrado Digital Media
WALTHAM, Mass., Sept. 16, 2021 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it has entered into a definitive agreement to acquire privately-held Avitide Inc., for approximately $150 million, comprised of $75 million in cash plus $75 million in Repligen common stock in addition to performance-based earnout payments over the next three years. Avitide is a leading chromatography developer with diverse affinity ligand libraries and best-in-class ligand-to-resin development timelines.
   2021-2027 Tangential Flow Filtration Market Trending Technologies, Remarkable Developments and Key Players like GE, Merck, Sartorius, Repligen, Parker Hannifin, Sterlitech, Bionet  2021/09/27 11:07:47 OpenPR
Overview of Global Tangential Flow Filtration Market: The universal Tangential Flow Filtration Market report gives us an in-depth overview of the research trends for the financial year 2021. The base year for calculation in the report is taken as 2020 while
   The Daily Biotech Pulse: Pfizer-BioNTech US Vaccine Contract, Summit Slumps On Adverse Regulatory Feedback, Cerevel CFO Departs  2021/09/22 11:45:28 Benzinga
Here''s a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 20) Acceleron Pharma Inc. (NASDAQ: XLRN ) Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH ) C4 Therapeutics, Inc. (NASDAQ: CCCC ) Cerevel Therapeutics Holdings, Inc. (NASDAQ: CERE ) Corvus Pharmaceuticals, Inc. NASDAQ: CRVS) Fulcrum Therapeutics, Inc. (NASDAQ: FULC ) IVERIC bio, Inc. (NASDAQ: ISEE ) Leap Therapeutics, Inc. (NASDAQ: LPTX ) Opiant Pharmaceuticals, Inc. (NASDAQ: OPNT ) Repligen Corporation (NASDAQ: RGEN ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows Sept. 20) Ambrx Biopharma Inc. (NYSE: AMAM ) Absci Corporation (NASDAQ: ABSI ) Acutus Medical, Inc. (NASDAQ: AFIB ) Aytu Biopharma, Inc. (NASDAQ: AYTU ) AzurRx BioPharma, Inc. (NASDAQ: AZRX ) Biomea Fusion, Inc. (NASDAQ: BMEA ) Centessa Pharmaceuticals Limited (NASDAQ: CNTA ) Codex DNA, Inc. (NASDAQ: DNAY ) Emergent BioSolutions Inc. (NYSE: EBS ) Galapagos NV (NASDAQ: GLPG ) Harpoon Therapeutics, Inc.
   The Daily Biotech Pulse: Leap, Phio, Silverback Among Early Movers On Oncology Conference Presentations, Aerie Slumps On Mixed Data, Axsome Commences Phase 3 Sleep Disorder Study  2021/09/16 11:48:49 Benzinga
Here''s a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 15) Alcon Inc. (NYSE: ALC ) Bicycle Therapeutics plc (NASDAQ: BCYC ) Bio-Techne Corporation (NASDAQ: TECH ) Cytek Biosciences, Inc. (NASDAQ: CTKB ) Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA ) IVERIC bio, Inc. (NASDAQ: ISEE ) Kezar Life Sciences, Inc. (NASDAQ: KZR ) Opiant Pharmaceuticals, Inc. (NASDAQ: OPNT ) Repligen Corporation (NASDAQ: RGEN ) Vera Therapeutics, Inc. (NASDAQ: VERA ) Zentalis Pharmaceuticals, Inc. (NASDAQ: ZNTL ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows Sept. 15) 4D pharma plc (NASDAQ: LBPS ) (announced biomarker analyses from two studies of MRx0518 in solid tumor settings) Achilles Therapeutics plc (NASDAQ: ACHL ) Acutus Medical, Inc. (NASDAQ: AFIB ) Aditxt, Inc. (NASDAQ: ADTX ) Applied Molecular Transport Inc. (NASDAQ: AMTI ) Ardelyx, Inc. (NASDAQ: ARDX ) AzurRx BioPharma, Inc. (NASDAQ: AZRX ) CVRx, Inc. (NASDAQ: CVRX ) Dermata Therapeutics, Inc.
   Repligen acquires Avitide in cash and stock deal of $150M  2021/09/16 11:47:27 Seeking Alpha
   Repligen Announces Agreement to Acquire Avitide Inc.  2021/09/16 11:40:00 Intrado Digital Media
WALTHAM, Mass., Sept. 16, 2021 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it has entered into a definitive agreement to acquire privately-held Avitide Inc., for approximately $150 million, comprised of $75 million in cash plus $75 million in Repligen common stock in addition to performance-based earnout payments over the next three years. Avitide is a leading chromatography developer with diverse affinity ligand libraries and best-in-class ligand-to-resin development timelines.
   Repligen Corp (RGEN): Price Up $2.36 (1.22)% Over Past Day, Up $0.96 (0.49)% Over Past Hour  2021/06/24 15:10:55 ETF Daily News
Regarding the trend, note that the strongest trend exists on the 100 day timeframe. The post Repligen Corp (RGEN): Price Up $2.36 (1.22)% Over Past Day, Up $0.96 (0.49)% Over Past Hour appeared first on ETF Daily News .
   Repligen To Buy Polymem For An Undisclosed Sum  2021/06/22 11:20:23 Benzinga
Repligen Corporation (NASDAQ: RGEN ) has agreed to acquire France-based Polymem S.A. , a provider of hollow fiber membranes and modules. "The acquisition significantly expands our hollow fiber membrane and module production capabilities and adds core R&D, engineering, and production Full story available on Benzinga.com
   Repligen inks an agreement to acquire Polymem S.A.  2021/06/22 10:44:52 Seeking Alpha
   Global Protein A Resin Market : Expecting Major Surge in Revenue in Next FIVE Years..!  2021/06/01 07:00:00 EmailWire Press Releases
( EMAILWIRE.COM , June 01, 2021 ) The study involved four major activities in estimating the current size for the protein A resin market . Exhaustive secondary research was done to collect information on the market and its different subsegments. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. [140 Pages Report] The protein A resin market is expected to reach USD 1.9 billion by 2025 from USD 1.1 billion in 2020, at a CAGR of 11.4% during the forecast period. The growth in this market is mainly driven by the growing demand for disposable pre-packed columns, increasing demand for therapeutic antibodies, and the increasing pharmaceutical R&D spending are expected to drive the growth of this market during the forecast period. However, the high cost of resins is expected to limit the growth of this market. Market Dynamics 1. Growing demand for disposable pre-packed columns 2. Increasing demand for therapeutic antibodies 3.
   Repligen Corporation to Present at Upcoming Investor Conferences  2021/05/25 11:30:00 GlobeNewswire
WALTHAM, Mass., May 25, 2021 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will present virtually at two upcoming investor conferences.

 関連キーワード  (医薬品 米国株 レプリジェン RGEN Repligen Corporation)

 twitter  (公式ツイッターやCEOツイッターなど)